LXRX Lexicon Pharmaceuticals Inc.

5.75
-0.01  -0%
Previous Close 5.76
Open 5.8
Price To Book -13.37
Market Cap 611,063,580
Shares 106,271,927
Volume 381,524
Short Ratio
Av. Daily Volume 461,808

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 trial did not meet primary endpoint.
Sotagliflozin
Type 1 Diabetes
CRL issued March 22, 2019.
Sotagliflozin
Type 1 Diabetes
Approved February 28, 2017.
Telotristat etiprate (XERMELO)
Carcinoid Syndrome
Phase 3 data due 4Q 2019 or 1Q 2020.
Sotagliflozin
Type 2 Diabetes
Phase 1b top-line data due 2H 2019.
LX9211
Neuropathic pain
Phase 2a initiation of dosing announced March 15, 2019. Top-line data due 2020.
Telotristat ethyl - TELE-ABC
Biliary tract cancer (BTC)

Latest News

  1. Should You Be Pleased About The CEO Pay At Lexicon Pharmaceuticals, Inc.'s (NASDAQ:LXRX)
  2. See what the IHS Markit Score report has to say about Lexicon Pharmaceuticals Inc.
  3. Lexicon Pharmaceuticals to Present New Clinical Data at 79th American Diabetes Association Scientific Sessions
  4. Lexicon Pharmaceuticals to Present at Upcoming Investor Conference
  5. Edited Transcript of LXRX earnings conference call or presentation 1-May-19 12:00pm GMT
  6. Here’s What Hedge Funds Think About Lexicon Pharmaceuticals, Inc. (LXRX)
  7. Lexicon Pharmaceuticals (LXRX) Reports Q1 Loss, Lags Revenue Estimates
  8. Lexicon Pharmaceuticals Inc (LXRX) Q1 2019 Earnings Call Transcript
  9. Lexicon: 1Q Earnings Snapshot
  10. Lexicon Pharmaceuticals Reports First Quarter 2019 Financial Results and Provides a Business Update
  11. ZynquistaTM now approved in the European Union for treatment of adults with type 1 diabetes
  12. Zynquista™ now Approved in the European Union for Treatment of Adults With Type 1 Diabetes
  13. Will Lexicon Pharmaceuticals (LXRX) Report Negative Q1 Earnings? What You Should Know
  14. Lexicon Pharmaceuticals to Host First Quarter 2019 Financial Results Conference Call and Webcast on May 1, 2019
  15. Did You Manage To Avoid Lexicon Pharmaceuticals's (NASDAQ:LXRX) Painful 55% Share Price Drop?
  16. CLASS ACTION UPDATE for LXRX, BRS, WTW and AMR: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders